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doi:10.1016/j.jmii.2012.04.002Background: Stenotrophomonas maltophilia is an emerging pathogen causing invasive infec-
tions in immunocompromised pediatric patients, including neonates and pediatric oncology
patients. Information on innate immune responses to S. maltophilia and its potential modula-
tion are scarce.
Methods: We established an in vitro S. maltophilia whole blood sepsis model and studied the
proinflammatory cytokine production of CD14-positive cells by flow cytometry. We compared
the cytokine expression of term newborns (nZ 13) and healthy adults (nZ 10) and investi-
gated in vitro responses of pediatric oncology patients after recovery from neutropenia
(nZ 10) with healthy adults (nZ 10). We further evaluated the immunomodulatory role of
the amino-acid derivative taurolidine in our in vitro sepsis model.
Results: Proinflammatory cytokine responses to S. maltophilia were largely diminished in the
neonatal population. No remarkable differences were noted for cytokine responses between
pediatric oncology patients and healthy controls. Taurolidine inhibited immunoglobulin (IL)-6,
IL-8 and tumor necrosis factor-alpha expression in a dose dependent-fashion in both, pediatric
oncology patients and healthy controls.
Conclusion: Deficient immune responses to S. maltophilia require optimized prevention strat-
egies against infection in immunocompromised patients, including neonates. Taurolidine may
be an effective immunomodulatory agent in a clinical setting.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Paediatrics, University of Lu¨beck, Ratzeburger Allee 160, 23538 Lu¨beck, Germany.
l.mu-luebeck.de (C. Ha¨rtel).
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116 C. Ha¨rtel et al.Introduction white blood cell count  2 106/mL; surgically insertedStenotrophomonas maltophilia is an emerging gram-
negative pathogen with significance for susceptible indi-
viduals, including patients with malignant diseases
undergoing myeloablative therapy and cystic fibrosis
patients. S. maltophilia is frequently found in patient
respiratory secretions and may therefore cause infectious
exacerbations or ventilator-associated pneumonia. Other
reservoirs include the gastrointestinal tract fluids that are
used in the hospital environment (e.g., parenteral nutri-
tion). Although the virulence factors of S. maltophilia are
limited, patients with indwelling central venous catheters
are at particular risk for subsequent infection.1 In recent
years, S. maltophilia infections were also reported in
neonatal intensive care units, in particular in infants with
need for mechanical ventilation, total parenteral nutri-
tion, or long-term stay in hospital.2 A better understanding
of host risk factors would help to improve prevention and
treatment strategies of S. maltophilia exposure. It was the
aim of this study to establish an in vitro S. maltophilia
sepsis model and to investigate cytokine responses in
whole blood monocytes of immunocompromised individ-
uals such as neonates and pediatric oncology patients.
Furthermore, the management of S. maltophilia infec-
tions is complicated by the inherent resistance to multiple
antibiotics. In fact, current national guidelines are reluc-
tant to recommend a standardized treatment regimen for
S. maltophilia infection, or employ in vitro testing for co-
trimoxazole. However, there is a need for therapeutic
options beyond co-trimoxazole that is myelosuppressive
and may cause bilirubin encephalopathy in susceptible
neonates. Alternative treatment strategies include
combinations of ciprofloxacin, ticarcillin-clavulanate or
ceftazidime/ceftriaxone.3 In order to face the issue of
antibiotic resistance, the development of new therapeutic
agents remains evident. One potential antimicrobial
candidate is taurolidine [bis-(1,1-dioxoperhydro-1,2,
4-thiadiazinyl-4)methane], a derivative of the amino-acid
taurine with broad-range antibacterial and antifungal
activity.4e6 Its mechanism of action is presumably medi-
ated by methylol derivatives that irreversibly destroy
bacterial cell walls7 or hamper biofilm production.8 In
addition, taurolidine may have an immunomodulatory
potential including antiinflammatory properties in
lipopolysaccharide-stimulated monocytes and inhibitory
effects on bacterial adherence to epithelial cells.9e11 In
this study, we evaluated the immunomodulatory role of
taurolidine in our in vitro S. maltophilia sepsis model.
Methods
Study population
Cord blood samples were taken after parental informed
consent from healthy term newborns (nZ 13, gestational
age 37e41 weeks). Peripheral venous blood samples from
healthy adult blood donors (nZ 10) served as controls.
Blood samples of pediatric oncology patients were with-
drawn after recovery from neutropenia before the next
cycle of chemotherapy was commenced (inclusion criteria:central venous line). The cohort of pediatric oncology
patients consisted of three patients with acute lympho-
blastic leukemia, three with neuroblastoma, one soft tissue
sarcoma, one ependymoma, one nephroblastoma, one
Hodgkin disease (age in years; mean/median/95% CI: 10.7/
11.7/6.2e15.2), and their data were compared with
healthy blood donors. Informed consent was given for all
subjects, and the study was approved by the ethics
committee of the University of Lu¨beck.
Whole blood assay
Heparinized whole blood was suspended in Roswell Park
Memorial Institute (RPMI) 1640 supplemented with 1% peni-
cillin/streptomycin, 2 mM glutamine, 1 mM pyruvate, and
nonessential amino acids (Seromed Biochrome, Berlin,
Germany) at a concentration of 5 106 leukocytes/ml. A total
of 5 106 [one colony forming unit (CFU)/white blood
cell(WBC)] or 5 107 (10 CFU/WBC) vital bacteria (S. malto-
philia, derived from a preterm infant born at 28 weeks of
gestation who developed S. maltophilia sepsis) were added
and whole blood cultures were incubated for 4 hours. Stimu-
lation experiments with 30 ng/ml lipopolysaccharide [(LPS)
Sigma/Deisenhofen, Germany] and 5 106 vital Staphylo-
coccus epidermidis served as positive controls. As a negative
control, only phosphate buffered saline (PBS) buffer was
added.
The cells were washed in PBS, incubated with a buffer
containing 4% paraformaldehyde (Riedel de Haen, Seelze,
Germany) for another 10 minutes and washed again in PBS.
They were resuspended in milk 5% and stored at 4C
overnight.
Intracellular staining of cytokines
Cells were washed in Hank’s buffered salt solution (HBSS)
and resuspended in a buffer consisting HBSS, 0.1% saponin
(Riedel de Haen) and 0.01 M Hydroxyethyl piper-
azineethanesulfonic acid (HEPES) buffer (Seromed Bio-
chrome). A total of 200 ml aliquots of cells were added to
tubes containing 0.5 mg/10 ml of monoclonal antibodies
[(Mabs) BD Pharmingen Heidelberg, Germany] against CD14
(M5E2, Phycoerythrin-cyanine (PC)5 conjugated), immuno-
globulin (IL)-6 (MQ2-13A5, Fluorescein Isothiocyanate
(FITC)-conjugated), IL-8 (G265-8 Phycoerythrin (PE)-
conjugated) and tumor necrosis factor (TNF)-alpha (Mab11,
FITC-conjugated). Preincubation with a surplus of uncon-
jugated anticytokine Mabs (5 mg/10 ml, Pharmingen) served
as a negative control for intracellular staining to each
sample. Isotype-specific antibodies were used to detect
irrelevant specificity for surface molecule staining. Flow
cytometric analysis was performed on BD FACS Canto
(Heidelberg, Germany). Data were expressed as percentage
of stimulated whole blood cells (CD14þ monocytes) positive
for individual cytokine production.12
Statistical analysis
Statistical differences were tested for nonpaired data with
the Mann-Whitney U-test, for paired data using Wilcoxon-
80
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Immune responses to S. maltophilia 117rank sum test. Statistical analyses were performed using
SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA).%
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Whole blood in vitro sepsis model with S.maltophilia
In all different age groups we were able to demonstrate
that S. maltophilia induces proinflammatory cytokine
production in whole blood cultures comparable to stimu-
lation with LPS. For example, pediatric oncology patients
(nZ 10); median number of cytokine expressing CD14þ
cells, 95% confidence interval (CI), unstimulated versus
stimulated with 1 CFU/WBC S. maltophilia; IL-6: 0.25%,
0.03e1.2% versus 28.7%, 13.6e42.9%, pZ 0.005; IL-8: 4.0%,
2.3e8.8% vs. 64.3%, 54.8e79.1%, pZ 0.005; TNF-alpha:
0.05%, 0.03e0.3% vs. 13.6%, 10.7e21.6%, pZ 0.005.
These data are shown in Figs. 1 and 2.
In addition to that, an inoculation-dose dependent
stimulation of IL-6 and TNF-alpha responses was observed
in both, cord blood samples and peripheral blood samples
from adults (Fig. 1AeC).%
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in neonates
As described in Fig. 1, neonates display a deficient IL-8 and
TNF-alpha response as compared to adults after LPS stim-
ulation and S. maltophilia inoculation of whole blood
samples. With regard to IL-6, reduced levels were only
found in cord blood levels stimulated with 1 CFU/WBC
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Figure 1. Deficient neonatal pro-inflammatory cytokine
responses in the S. maltophilia in vitro sepsis model. The figure
depicts the intracellular expression of (A) IL-6; (B) IL-8; and (C)
TNF-alpha in CD14 þ cells after incubation with PBS (control),
30 ng/ml LPS or with S. maltophilia 1 or 10 CFU/WBC. Neonatal
(white boxes, nZ 13) and adult data (grey boxes, nZ 10) are
presented as box plots indicating median (95% CI, 25% and 75%
quartiles and outliers) percentage of cytokine expressing CD14þ
cells. P-values are derived from Mann-Whitney U-test, a p val-
ue< 0.05 was regarded as significant. CIZ confidence interval;
CFUZ colony forming unit; ILZ immunoglobulin; LBSZ lipo-
polysaccharide; PBSZ phosphate buffered saline; TNFZ tumorS. maltophilia in vitro responses in pediatric
oncology patients with central venous device
and effect of taurolidine
As outlined in Fig. 2, the proinflammatory cytokine
expression (IL-6, IL-8, TNF-alpha) of several in vitro sepsis
models (LPS; 1 CFU/WBC S. epidermidis and 1 CFU/WBC
S. maltophilia) did not differ between pediatric oncology
patients and healthy adult controls.
We also tested the effect of different concentrations of
taurolidine after pre-incubation of whole blood cultures of
patients and controls for 1 hour (Fig. 3). Again, no signifi-
cant differences were noted between patients and
controls. We were able to demonstrate that addition of
20 mg/ml taurolidine to whole blood samples of pediatric
oncology patients caused a significant inhibition of IL-6
(median number of cytokine expressing CD14þ cells, 95%
CI 28.7%, 13.6e42.9% vs. 2.4%, 0.05e17.4%, pZ 0.005,
nZ 10) and TNF-alpha (13.6%, 10.7e21.6% vs. 3.9%,
2.2e10.4%, pZ 0.005), while lower concentrations (1, 5,
and 10 mg/ml) had no significant effect. A concentration of
50 mg/ml taurolidine was needed to affect patients’ IL-8
expression (64.3%, 54.8e79.1% vs. 2.0%, 0.7e4.2%,
pZ 0.005). Similar results were noted for healthy adult
controls (Fig. 3AeC).necrosis factor; WBCZwhite blood cell.
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Figure 2. S. maltophilia in vitro responses in pediatric
oncology patients with central venous device. The figure
depicts the intracellular expression of (A) IL-6; (B) IL-8; and (C)
TNF-alpha in CD14 þ cells after incubation with 30 ng/ml LPS,
l CFU/WBC S. epidermidis or with 1 CFU/WBC S. maltophilia.
Data of patients (white boxes, nZ 10) and healthy adult
controls (grey boxes, nZ 10) are presented as box plots indi-
cating median (95% CI, 25% and 75% quartiles and outliers)
percentage of cytokine expressing CD14þ cells. No statistical
differences exist (Mann-Whitney U-test). CIZ confidence
interval; CFUZ colony forming unit; ILZ immunoglobulin;
LBSZ lipopolysaccharide; TNFZ tumor necrosis factor;
WBCZwhite blood cell.
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Figure 3. Effect of taurolidine in the S. maltophilia in vitro
sepsis model. The figure depicts the intracellular expression of
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In this study, we established an in vitro S. maltophilia
sepsis model and determined proinflammatory cytokine
responses in whole blood monocytes of immunocompro-
mised individuals such as neonates and pediatric oncology
patients. In line with previous data regarding exposure to
various antigenic or microbial stimuli,13 neonates dis-
played a reduced, immature cytokine response to S.
maltophilia that underlines the basic concept of suscep-
tibility to infection in these vulnerable patients. Innate
immune pathways represent the first defence mechanism
for neonates, and maturation of immune responses is an
essential part of early postnatal development.14 On the
other hand, impairment of adequate cytokine regulation
in neonates (or disturbed balance in the “inflammatory
situation”) might be another key element for adverse
outcomes associated with gram-negative bacilli infection
in newborns.15 Recent epidemiologic data indicate that
S. maltophilia is an emerging pathogen on neonatal
intensive care units,2 and likewise for pediatric oncology
patients.1,16e19 Due to several intrinsic and acquired
resistance mechanisms of S. maltophilia, the choice of
adequate antibiotic treatment is difficult.20 Thus preven-
tive strategies are of high importance, particularly
hygienic measures, restriction of invasive procedures
including mechanical ventilation and insertion of central
venous lines.21 The taurine derivative taurolidine proved
to be a promising alternative to antibiotic agents as it has
antimicrobial and immunomodulatory capacities and no
resistance patterns have been described yet.
In our in vitro setting we were able to demonstrate that
pediatric oncology patients after recovery from neutropenia
are able to mount an adequate proinflammatory cytokine
response against whole S. maltophilia bacteria, which may
be sufficiently reversed by addition of taurolidine to whole
blood in a concentration of 20e50 mg/mL. Compared with
minimal inhibitory concentrations (MIC) to kill S.maltophilia
ranging from 500e1000 mg/ml,6 anti-inflammatory proper-
ties are evident at much lower concentrations. While several
prospective studies showed that taurolidine-
lock-solutions reduce the rate of central venous access
device (CVAD)-associated infections,22e25 relevant blood-
stream concentrations may, however, counter-regulate
a systemic proinflammatory response. On one hand, this
phenomenon might be associated with an increased risk of
a deficient first-line response against S. maltophilia; on the(A) IL-6; (B) IL-8; and (C) TNF-alpha in CD14 þ cells after
incubation with 1 CFU/WBC S. maltophilia co-incubated with
different concentrations of taurolidine. Pediatric oncology
patients (white boxes, nZ 10) and healthy adult controls (grey
boxes, nZ 10) are presented as box plots indicating median
(95% CI, 25% and 75% quartiles and outliers) percentage of
cytokine expressing CD14þ cells. Statistical differences (co-
incubated cultures vs. controls; Wilcoxon-Rank-Sum test) are
indicated as asterisks. No statistical differences exist between
patients and controls (Mann-Whitney U-test). **p< 0.005.
***p< 0.0005. CIZ confidence interval; CFUZ colony forming
unit; ILZ immunoglobulin; TNFZ tumor necrosis factor;
WBCZwhite blood cell.other hand, the counter-regulatory potential could be
beneficial to prevent systemic inflammation and organ
failure. We noted that the immunomodulatory effect is
concentration-dependent in both pediatric oncology
patients and healthy controls. Even if concentrations of
100 mg/mlwere applied, no cytotoxic effectswere observed.
Previous data indicate that taurolidine might be considered
as antimicrobial agent for local application in lock or flushing
solutions of central venous lines; in our experience, it may
also be applied for counter-regulation of exaggerated
proinflammatory responses in an S. maltophilia sepsis situ-
ation which needs to be further studied in an animal model.
There are limitations to this study. First, we used cord
blood samples of healthy term neonates that do not reflect
the cohort of extremely vulnerable preterm infants.
Furthermore age-dependent maturation processes occur in
early childhood that do not allow to superimpose our data
to all pediatric oncology patients at all age groups. Second,
we only investigated monocyte responses in our setting,
while cytokine networks are based on additional immune
cell types such as lymphocytes, dendritic cells and endo-
thelial cells. Moreover, we described a survey of a limited
selection of pro-inflammatory markers for the immune
system rather than a hypothesis-driven study of individuals
“at risk.” In addition, our in vitro whole blood assay
preserves physiologic concentrations of factors involved in
innate immune responses but can only serve as a model for
the in vivo situation. Third, the case numbers in all
experimental groups were small, and future studies will
need to evaluate whether the immunomodulatory effect of
taurolidine improves clinical outcome.
In summary, deficient immune responses to S. malto-
philia require optimized prevention strategies against
infection in vulnerable patient cohorts including neonates.
Taurolidine may be an effective immunomodulatory agent
in a clinical setting.
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